Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors

Abstract

Programmed death 1 ligand (PD-L1), an important immune checkpoint molecule, is mainly expressed on cancer cells and has been shown to exert an immunosuppressive effect on T-cell function by binding to programmed cell death 1 (PD-1) expressed on T-cells. Recently, immune checkpoint inhibitors using antibody drugs such as nivolumab and atezolizumab have attracted attention. However, clinical challenges, including limitations to the scope of their application, are yet to be addressed. In this study, we developed a novel immune checkpoint inhibitor that targets PD-L1 using lipid-siRNA conjugates (lipid-siPDL1s). The inhibitory effect of lipid-siPDL1s on PD-L1 expression was evaluated and found to strongly suppress mRNA expression. Notably, lipid-siPDL1s exerted a significantly stronger effect than unmodified siPDL1. Interestingly, lipid-siPDL1s strongly inhibited PD-L1 expression despite cancer cell stimulation by interferon-gamma, which induced the overexpression of PD-L1 genes. These results strongly suggest that lipid-siPDL1s could be used as novel immune checkpoint inhibitors.